Clinical trial · Interventional
Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of High-grade Lesions and/or Anal Cancer 10 Years After Inclusion in the ANRS IPERGAY Trial
NCT06522256CI-TRIAL-00098453HPVsignrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
HPVsign is a cross-sectional, non-comparative, multicenter study involving all participants included in the HPV substudy of the ANRS IPERGAY trial. The study proposes to evaluate the cumulative incidence of high-grade lesions and/or anal cancers using high-resolution anoscopy (HRA) during the HPVsign study and/or diagnosed since the end of participation in the ANRS IPERGAY trial.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
| HPV Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High-resolution anoscopy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- High-resolution anoscopy
- interventionNames
- Procedure: High-resolution anoscopy
Primary outcomes (1)
- measure
- High-Grade Squamous Intraepithelial Lesion (HSIL) and/or anal cancers diagnosed by an high-resolution anoscopy (HRA)
- timeFrame
- Within the 10 years prior to HPV sign study participation, or at the study proctological examination in the study.
Secondary outcomes (5)
- measure
- HPV molecular signatures obtained using the Capture-HPV technique: HPV mutations, integration into the human genome
- timeFrame
- at the time of the ANRS IPERGAY-HPV sub-study, and 10 years later, in the HPVsign study.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participant in the ANRS IPERGAY clinical trial who was included in the initial HPV sub-study; * Informed and written signed consent * Participant with regular health insurance Exclusion Criteria: * Participant under guardianship or curatorship * Participant with free State medical assistance * Participant who disagrees with the use of data collected as part of their participation in the ANRS IPERGAY trial.
References
Publications (0)
Data not yet available
No reference posted for this study.